Highland Capital Management LLC Invests $1.76 Million in Gilead Sciences, Inc. $GILD

Highland Capital Management LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 15,819 shares of the biopharmaceutical company’s stock, valued at approximately $1,756,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Rothschild Investment LLC boosted its holdings in shares of Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares during the period. Ignite Planners LLC lifted its position in shares of Gilead Sciences by 1.1% in the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after acquiring an additional 86 shares in the last quarter. Archer Investment Corp boosted its stake in Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the period. Binnacle Investments Inc grew its position in Gilead Sciences by 14.3% during the 2nd quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 88 shares in the last quarter. Finally, EPG Wealth Management LLC grew its position in Gilead Sciences by 2.0% during the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 89 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This represents a 67.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the transaction, the chief financial officer directly owned 153,503 shares in the company, valued at approximately $18,727,366. This represents a 1.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 136,257 shares of company stock valued at $16,723,492. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

NASDAQ GILD opened at $124.70 on Friday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $154.71 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 0.70 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The company has a 50 day moving average price of $122.95 and a two-hundred day moving average price of $116.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 EPS. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is currently 48.99%.

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 20th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Finally, Rothschild & Co Redburn increased their target price on shares of Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $131.54.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.